Chicago Consortium Women's Interagency HIV Study lll

描述（由申请人提供）作为一项多中心、前瞻性队列研究，妇女机构间艾滋病毒研究（WIHS）旨在直接解决与妇女艾滋病毒自然史和临床表现相关的关键假设。 WIHS-III期间（12/02-11/07），WIHS的科学目标是：1）开发、完善和评价抗逆转录病毒治疗（ART）暴露的综合指标，并将这些指标与HIV疾病进展的标志物联系起来，2）确定HIV-1感染的治疗史和临床、对高效抗逆转录病毒治疗（HAART）的病毒学和免疫学应答，3）评价与ART相关的不良事件，4）研究HIV和HMRT的使用对导致HIV感染或有HIV风险的女性疾病的病毒合并感染的发生率/自然史的长期影响，重点关注人乳头瘤病毒感染和宫颈肿瘤，丙型肝炎病毒感染和肝脏疾病，5）评估年龄，排卵功能，绝经及其治疗对HIV感染过程和对ART反应的影响，6）描述女性HIV相关癌症的流行病学，并进一步定义HAART女性恶性肿瘤的自然史，（7）评估HIV疾病的口腔表现。 芝加哥WIHS将利用其9年成功的保留策略，在4个临床研究中心吸引并保留390名参与者（295名HIV阳性，95名HIV-），包括150名口腔研究中心的参与者，为期6个月。 这些将包括访谈、检查、血液、妇科和口腔标本、病历摘要、登记匹配以及当地和集中实验室分析。 芝加哥WIHS将提供最高质量的数据，领导和参与流行病学分析，并传播从这项研究计划中获得的结果和科学信息。 作为我们针对特定地点的科学举措，我们将调查接受HMRT的HIV感染妇女的免疫恢复情况，特别关注年龄、药物使用、外源性激素和绝经对免疫恢复的影响。

DESCRIPTION (provided by applicant) As a multicenter, prospective cohort study The Women's Interagency HIV Study (WIHS) is designed to directly address key hypotheses related to the natural history and clinical manifestation of HIV among women. During WIHS-III (12/02-11/07), WIHS scientific Aims are to 1) develop, refine, and evaluate composite measures of antiretroviral therapy (ART) exposure and relate these measures to markers of HIV disease progression, 2) define the treated history of HIV-1 infection and the individual determinants, including host and viral genetic factors, of clinical, virologic and immunologic response to highly-active antiretroviral therapy (HAART), 3) evaluate adverse events associated with ART, 4) investigate the long term effects of HIV, and use of HMRT, on the incidence/natural history of viral co-infections that cause disease in women with or at risk for HIV, focusing on human papillomavirus infection and cervical neoplasia, and hepatitis C virus infection and liver disease, 5) evaluate the effects of age, ovulatory function, menopause and its treatment on the course of HIV infection and response to ART, 6) describe the epidemiology of HIV- associated cancers in women, and further define the natural history of malignancies in women on HAART , and 7) evaluate the oral manifestations of HIV disease. Chicago WIHS will use its nine years of successful retention strategies to engage and retain 390 participants (295 HIV+, 95 HIV-) at four clinical sites including150 participants at the oral site through six month visit cycles. These will include interviews, exams, blood, gynecologic and oral specimens, medical record abstractions, registry matches, and local and centralized laboratory analysis. Chicago WIHS will contribute the highest quality data, lead and participate in epidemiologic analyses, and disseminate the results and scientific information learned from this research initiative. As our site-specific scientific initiative, we will investigate immune recovery in HIV infected women on HMRT with particular interest in the effects of age, drug use, exogenous hormones and menopause on immune recovery.